COCP

Cocrystal Pharma, Inc. (COCP) | Rumor.io

Cocrystal Pharma

COCP

Attention (50-day avg)0%

Attention rank (50-day avg)#2,763

Bullish sentiment (50-day avg)89%

Price to earnings ratio-1.56

Market capitalization23.3M

Earnings per share-0.75

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.8M

Social

What share of all stock conversation is about COCP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Aug 3

Cocrystal Pharma, Inc. (COCP) has announced a $5 million private placement with OPKO Health, with OPKO purchasing 5,474,053 shares at $0.9134/share.
The private placement is expected to be used for drug development and corporate needs, with OPKO already being a longtime investor and co-founder Phillip Frost's company.
The deal is seen as a positive development for COCP, with some analysts noting the potential for a short squeeze due to the company's low float and high short interest.

Generated by AI

Sentiment

Of the messages about COCP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +9.52	85.51% +5.37
Bearish	—	0%	0% -9.52	14.49% -5.37

Bullish· Apr 6

The asset has a tight range of 1.4 to 1.62, with a potential breakout expected tomorrow.
A bear hedge fund's attempt to short 100,000 shares was met with a strong buying response, indicating bullish sentiment.
The asset's trend is upward, with a potential move to $25 and accumulation of shares leading to a scarcity of available stock.

Bearish· Apr 6

The Cost-to-Borrow for COCP has increased dramatically, from 3.54 to over 200, suggesting price manipulation.
Shorts in COCP may face significant losses, with the stock potentially reaching $25.
COCP's current price may be unsustainable, with some speculating that a correction to $1.4 is necessary.

Generated by AI

Topics

Of the messages about COCP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	59.7%
Earnings	—	0%	0%	0.87%
Analysts	—	0%	0%	1.19%
Controversies	—	0%	0%	0.87%
Macro	—	0%	0%	30.34%
Technical Analysis	—	0%	0%	7.04%

Announcements· Sep 12

Cocrystal Pharma, Inc. (COCP) announced a registered direct offering of up to $13 million priced at-the-market under Nasdaq rules.
The company will issue warrants to purchase up to 5.53 million shares with an exercise price of $1.50 per share, below the offering's share purchase price of $1.70.
COCP presented CDI-988, its first oral antiviral candidate for Norovirus, at the International Calicivirus Conference, showing promise in Phase 1 safety studies and a Phase 1b human challenge study set to begin by year-end 2025.

Technical Analysis· Sep 12

Cocrystal Pharma, Inc. ($COCP) is watching for the $3.91 key pivot level for entry.
The stock has formed a bull flag and a parabolic move, with EMAs catching up fast, and is waiting for a breakout continuation or early signs of exhaustion.
$COCP needs to break through a descending wedge and a pennant to continue its upward momentum.

Generated by AI

Community

Of the messages about COCP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	84.38%	42.02%
Newcomers	100%	66.67%	15.63%	57.98%

Regulars· Sep 12

Cocrystal Pharma, Inc. ($COCP) has announced an up to $13 million registered direct offering, priced at-the-market under Nasdaq rules.
The company's CDI-988 product candidate has shown promise in a Phase 1 safety study, indicating potential for the first-ever oral drug in the $60B norovirus market.
Dr. Sam Lee, President and co-CEO of Cocrystal Pharma, Inc., has discussed the CDI-988 product candidate at an industry conference, highlighting the treatment's potential in the calicivirus space.

Newcomers· Apr 6

A new investigation report highlights CDI-988, a potential treatment for COVID-19 and its variants, which is in Phase 1 trials in Australia.
Cocrystal Pharma's stock is gaining attention after receiving a Fast Track designation, indicating a potential speedier regulatory review process.
The stock's price is rising, with a 4% increase, along with other small-cap stocks, which may be influenced by short-term traders' rotations.

Generated by AI

No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988

21d agoYahoo Finance

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.

29d agoYahoo Finance

Cocrystal Pharma appoints Carol L. Brosgart to board of directors

1mo agoInvesting.com

Cocrystal Pharma appoints Carol Brosgart to board of directors

1mo agoInvesting.com

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory. "Dr. Brosgart holds

1mo agoYahoo Finance

Also Discussed

Investors talking about COCP also mention

#	Name	Attention
1	Atea Pharmaceuticals, Inc.AVIR	0%0
2	AIM ImmunoTech Inc.AIM	0%0
3	OPKO Health, Inc.OPK	0%0
4	Nanoviricides Inc.NNVC	0%0
5	Willamette Valley Vineyards Inc.WVVI	0%0
6	Nemaura Medical Inc.NMRD	0%new
7	ENZ - Enzo Biochem, Inc.	——
8	Ernexa Therapeutics Inc.ERNA	0%0
9	ERYP - ERYTECH Pharma S.A.	——
10	BIOC - Biocept, Inc.	——

Cocrystal Pharma, Inc.

Healthcare
Biotechnology

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings. Its pipeline includes drug development efforts that span discovery, preclinical work, and clinical-stage studies, supported by structure-based technologies aimed at identifying differentiated antiviral compounds. Cocrystal Pharma also engages in research partnerships and funding activities that help advance its antiviral portfolio and related scientific programs. Headquartered in Bothell, Washington, Cocrystal Pharma plays a specialized role in the biotechnology market by addressing unmet needs in infectious disease therapeutics through targeted antiviral innovation.

Website

Location

19805 North Creek Parkway

Bothell, WA, 98011

United States

Social

What share of all stock conversation is about COCP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Aug 3

Cocrystal Pharma, Inc. (COCP) has announced a $5 million private placement with OPKO Health, with OPKO purchasing 5,474,053 shares at $0.9134/share.
The private placement is expected to be used for drug development and corporate needs, with OPKO already being a longtime investor and co-founder Phillip Frost's company.
The deal is seen as a positive development for COCP, with some analysts noting the potential for a short squeeze due to the company's low float and high short interest.

Generated by AI

Sentiment

Of the messages about COCP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +9.52	85.51% +5.37
Bearish	—	0%	0% -9.52	14.49% -5.37

Bullish· Apr 6

The asset has a tight range of 1.4 to 1.62, with a potential breakout expected tomorrow.
A bear hedge fund's attempt to short 100,000 shares was met with a strong buying response, indicating bullish sentiment.
The asset's trend is upward, with a potential move to $25 and accumulation of shares leading to a scarcity of available stock.

Bearish· Apr 6

The Cost-to-Borrow for COCP has increased dramatically, from 3.54 to over 200, suggesting price manipulation.
Shorts in COCP may face significant losses, with the stock potentially reaching $25.
COCP's current price may be unsustainable, with some speculating that a correction to $1.4 is necessary.

Generated by AI

Topics

Of the messages about COCP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	59.7%
Earnings	—	0%	0%	0.87%
Analysts	—	0%	0%	1.19%
Controversies	—	0%	0%	0.87%
Macro	—	0%	0%	30.34%
Technical Analysis	—	0%	0%	7.04%

Announcements· Sep 12

Cocrystal Pharma, Inc. (COCP) announced a registered direct offering of up to $13 million priced at-the-market under Nasdaq rules.
The company will issue warrants to purchase up to 5.53 million shares with an exercise price of $1.50 per share, below the offering's share purchase price of $1.70.
COCP presented CDI-988, its first oral antiviral candidate for Norovirus, at the International Calicivirus Conference, showing promise in Phase 1 safety studies and a Phase 1b human challenge study set to begin by year-end 2025.

Technical Analysis· Sep 12

Cocrystal Pharma, Inc. ($COCP) is watching for the $3.91 key pivot level for entry.
The stock has formed a bull flag and a parabolic move, with EMAs catching up fast, and is waiting for a breakout continuation or early signs of exhaustion.
$COCP needs to break through a descending wedge and a pennant to continue its upward momentum.

Generated by AI

Community

Of the messages about COCP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	84.38%	42.02%
Newcomers	100%	66.67%	15.63%	57.98%

Regulars· Sep 12

Cocrystal Pharma, Inc. ($COCP) has announced an up to $13 million registered direct offering, priced at-the-market under Nasdaq rules.
The company's CDI-988 product candidate has shown promise in a Phase 1 safety study, indicating potential for the first-ever oral drug in the $60B norovirus market.
Dr. Sam Lee, President and co-CEO of Cocrystal Pharma, Inc., has discussed the CDI-988 product candidate at an industry conference, highlighting the treatment's potential in the calicivirus space.

Newcomers· Apr 6

A new investigation report highlights CDI-988, a potential treatment for COVID-19 and its variants, which is in Phase 1 trials in Australia.
Cocrystal Pharma's stock is gaining attention after receiving a Fast Track designation, indicating a potential speedier regulatory review process.
The stock's price is rising, with a 4% increase, along with other small-cap stocks, which may be influenced by short-term traders' rotations.

Generated by AI

Cocrystal Pharma

Social

Aug 3

Bullish· Apr 6

Bearish· Apr 6

Announcements· Sep 12

Technical Analysis· Sep 12

Regulars· Sep 12

Newcomers· Apr 6

Cocrystal completes dosing in norovirus drug trial

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

Cocrystal Pharma appoints Carol L. Brosgart to board of directors

Cocrystal Pharma appoints Carol Brosgart to board of directors

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Also Discussed

Cocrystal Pharma, Inc.

Company Information

Location

Cocrystal completes dosing in norovirus drug trial

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

Cocrystal Pharma appoints Carol L. Brosgart to board of directors

Cocrystal Pharma appoints Carol Brosgart to board of directors

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Also Discussed

Social

Aug 3

Bullish· Apr 6

Bearish· Apr 6

Announcements· Sep 12

Technical Analysis· Sep 12

Regulars· Sep 12

Newcomers· Apr 6